Neural Progenitor Cells Derived from ATCC-DYS0530 Parkinson's Disease (ATCC® ACS-5001)

Organism: Homo sapiens, human  /  Cell Type: Neural Progenitor Cell (NPC)  /  Tissue: dermis  /  Disease: Parkinson's disease

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue dermis
Cell Type Neural Progenitor Cell (NPC)
Product Format frozen 1.0 mL
Morphology short spindle shape
Culture Properties adherent
Biosafety Level 2 [Cells contain Sendai viral DNA sequences]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Parkinson's disease
Age 63
Gender male
Ethnicity Caucasian
Applications Neuronal differentiation; drug and toxicological screening
Intended Use

Astrocyte, oligodendrocyte, and neuron differentiation; drug screening

Images Parkinsons NPC Marker Expression Parkinsons NPC Astrocyte Expression Parkinsons NPC Neuron Expression Parkinsons NPC Oligodendrocyte Expression
Derivation Parkinson's disease NPCs (ATCC® ACS-5001™) are derived from ATCC-DYS0530 Parkinson's disease Human [Caucasian Male] Induced Pluripotent Stem Cells (ATCC® ACS-1013™)

Antigen Expression Nestin, Pax-6
Comments Parkinson's disease research; astrocyte, oligodendrocyte, and neuron differentiation; drug screening, toxicology
Complete Growth Medium

Complete growth media for Neural Progenitor Cells (NPCs) includes DMEM: F12 (ATCC 30-2006) supplemented with the Growth Kit for Neural Progenitor Cell Expansion (ATCC ACS-3003). To make complete NPC medium add the following components of the kit to 464 mL DMEM: F12:

  • 5 mL L-Alanyl-L-Glutamine 
  • 5 mL Non-Essential Amino Acids
  • 10 mL NPC Growth Kit Component A 
  • 5 mL NPC Growth Kit Component B 
  • 1 mL NPC Growth Kit Component C 
  • 10 mL NPC Growth Kit Component D

Complete dopaminergic differentiation medium for NPCs is DMEM: F12 (ATCC 30-2006); supplemented with the Neural Progenitor Cell Dopaminergic Differentiation Kit (ATCC ACS-3004). To make complete NPC dopaminergic differentiation medium add the following components of this kit to 237 mL DMEM: F12:

  • 2.5 mL L-Alanyl-L-Glutamine
  • 2.5 mL Non-Essential Amino Acids + 0.5 mL Ascrobic Acid
  • 5 mL Dopaminergic Differentiation Kit Component A
  • 2.5 mL Dopaminergic Differentiation Kit Component B
  • 0.5 mL  Dopaminergic Differentiation Kit Component C
Also add CHIR-99021 (from Stemgent, catalog number 3003) to a final concentration of 5 µM (625 µl to 250 ml of media)
Seeding Density Post-thaw: 40,000 viable cells/cm2 on CellMatrix-coated dishes/plates
Subculture: 40,000 viable cells/cm2 on CellMatrix-coated dishes/plates
Subculturing

Post thaw day 1, perform a 100% medium change and remove all cells that did not attach. Perform a 100% medium change every other day thereafter. Passage the cells cells with diluted Accutase (50% Accutase and 50% DPBS) when they reach ~95% confluence and reseed the NPCs at 40,000 viable cells/cm2 on CellMatrix-coated dishes/plates.

Dopaminergic Differentiation: Seed NPCs at 10,000 cells/cm2 in a 12-well plate pre-coated with CellMatrix. Culture overnight in complete NPC expansion medium. The next day, aspirate the medium and add 1.5 ml of pre-warmed complete Dopaminergic Differentiation Medium containing CHIR. Change the Dopaminergic media every other day (e.g., Monday, Wednesday, and Friday) for 3 weeks as the following:

  1. For each media change in the process, gently remove approximately 85% of the medium using a 5 ml serological pipette from each well and discard.
  2. During the first week of the differentiation, slowly add 1.5 ml of fresh Dopaminergic Differentiation Medium to each well along the wall of the well on Monday and Wednesday; add 2 ml of of fresh Dopaminergic Differentiation Medium on Friday.
  3. During the second and third week of the differentiation, slowly add 2 ml of fresh Dopaminergic Differentiation Medium to each well along the wall of the well on Mondays and Wednesdays; add 2.5 ml of of fresh Dopaminergic Differentiation Medium on Fridays.
  4. Monitor NPC differentiation.
Culture Conditions

Coat plates with CellMatrix (ATCC ACS-3035) and culture the NPCs with NPC Growth Medium (ATCC ACS-3003) to provide a surface for the attachment of NPCs. Coating Procedure:

  1. Thaw CellMatrix Gel on ice and swirl gently to mix. Important: CellMatrix Gel will solidify in 15 to 30 minutes above 15°C. Keep CellMatrix Gel, vials and pipette tips on ice at all times to prevent CellMatrix Gel from solidifying. If air bubbles form, they may be eliminated by centrifuging CellMatrix Gel at 300 x g for 10 minutes at 2°C to 8°C.
  2. Determine the appropriate volume per aliquot based on concentration and usage. For seeding, plate cells at 40,000 viable cells/cm2 (1.50 x 106 cells/ well of 12-well plate).
  3. Dilute CellMatrix in DMEM:F12 to a working concentration of 150 μg/mL. Add 0.5 ml diluted CellMatrix gel per well of 12 well plate. 
  4. Cell culture dishes coated with CellMatrix Basement Membrane Gel should be incubated at 37°C for one hour. Aspirate coating solution and immediately plate the cells. It is critical that the coating does not dry out.
Cells per Vial 1 x 106
Volume 1.0 mL
STR Profile Amelogenin: X,Y
CSF1PO: 10,12
D13S17: 11
D16S539: 10,11
D5S818: 11,12
D7S820: 10,12
TH01: 7
TPOX: 8,11
vWA: 17,18
Sterility Tests Bacteria and yeast: No growth
Mycoplasma: No growth
Viral Testing None detected (CMV, EBV, HepB, HIV, and HPV)
Viability ≥ 80%
Functional Tests Exhibit differentiation potential of NPCs into Tuj1+ early neurons and TH+ dopaminergic neurons using NPC Expansion Medium (ACS-3003) and Dopaminergic Differentiation Kit (ACS-3004)
Population Doubling Time Approximately 42 hours when cultured in complete NPC growth medium
Name of Depositor ATCC
Year of Origin 2016
References

Malik N, et al. Compounds with species and cell type specific toxicity identified in a 2000 compound drug screen of neural stem cells and rat mixed cortical neurons. Neurotoxicology 45: 192-200, 2014. PubMed: 25454721

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
Restrictions

This product may be used by investigator for research purposes subject to the Limited Use Label License and any additional third party terms. This product is subject to claims under U.S. Patent Nos. 8,058,065 and 8,048,999, pending patent applications, and foreign counterparts thereof.  In addition, this product was generated using the proprietary technology of the DNAVEC Corporation, including, without limitation, recombinant Sendai virus vectors. For information on obtaining additional rights, please contact licensing@atcc.org

References

Malik N, et al. Compounds with species and cell type specific toxicity identified in a 2000 compound drug screen of neural stem cells and rat mixed cortical neurons. Neurotoxicology 45: 192-200, 2014. PubMed: 25454721